Johnson & Johnson delivered a robust financial performance for the first quarter of 2026, surpassing analyst projections on both the top and bottom lines. The healthcare giant reported quarterly revenue of $24.1 billion, representing a 9.9% year-over-year increase and exceeding the consensus estimate of $23.6 billion. Adjusted earnings per share came in at $2.70, also topping the $2.66 forecast by Wall Street.
Strong Start to the Year
Buoyed by these results, the company's management expressed confidence by raising its financial outlook for the full 2026 fiscal year. Johnson & Johnson nudged its midpoint for reported sales guidance to $100.8 billion, a slight increase from the previous $100.5 billion. Similarly, the adjusted earnings per share midpoint was raised to $11.55 from $11.53. Chief Executive Joaquin Duato characterized the period as a "strong start to 2026," highlighting recent regulatory approvals for new products like Icotyde in the United States and Varipulse Pro in Europe.
Segment Performance and the Stelara Transition
The company's performance was driven by strength across its key business segments. The Innovative Medicine division, which houses its pharmaceutical portfolio, saw sales jump 11.2% to $15.4 billion. The MedTech segment posted revenue of $8.6 billion, a 7.7% increase. This growth is critical as the company navigates a significant transition following the patent expiration of its blockbuster immunology drug, Stelara.
Stelara, which generated $10.36 billion in revenue in 2024, saw its sales plummet nearly 60% in the first quarter to $656 million. This decline follows the U.S. launch of Amgen's Wezlana, the first biosimilar competitor. The sharp drop underscores the high stakes for investors monitoring whether Johnson & Johnson's newer products can effectively offset this major revenue loss.
New Products Pick Up the Slack
Early signs are promising. Sales of the cancer therapy Darzalex soared to $4.0 billion for the quarter, significantly outpacing analyst expectations of $3.4 billion. Similarly, the psoriasis drug Tremfya generated $1.6 billion in revenue, handily beating the $1.2 billion estimate. According to Chief Financial Officer Joseph Wolk, the company is successfully capturing market share with Tremfya as patients transition from Stelara to other branded therapies rather than immediately switching to biosimilars.
The commercial success of these established drugs is now being supplemented by new launches. The company is pinning hopes on Icotyde, a once-daily oral pill for psoriasis that targets the IL-23 protein. This entry places Johnson & Johnson in direct competition with established rivals like Bristol Myers Squibb's Sotyktu and AbbVie's Skyrizi. Analysts, such as Guggenheim's Vamil Divan, suggest that if Icotyde's clinical data holds up in real-world use, physician adoption could occur rapidly.
Challenges on the Horizon
Despite the positive quarter, management outlined several challenges. The company warned that additional rounds of China's volume-based procurement program—a state-led bulk-buying initiative that aggressively lowers drug prices—could exert more pressure on results in the second half of the year. Furthermore, CFO Joseph Wolk publicly criticized proposals for "most-favored-nation" pricing mechanisms in U.S. law, describing them as a "back door to price controls" that would tie American drug costs to lower international prices.
Market Reaction and Future Outlook
Following the earnings release, Johnson & Johnson's stock experienced modest movement, slipping 0.27% to $237.96 in early trading. This comes after the shares had climbed approximately 15% year-to-date ahead of the report. The market's tempered response may reflect the modest scale of the guidance increase and the ongoing uncertainty surrounding the company's ability to fully compensate for Stelara's decline over the coming quarters.
In summary, Johnson & Johnson's first-quarter results demonstrate a successful initial phase in managing a pivotal product transition. While newer immunology and oncology drugs like Darzalex, Tremfya, and the newly launched Icotyde are effectively picking up the slack, the margin for error remains slim. The coming quarters will serve as the ultimate test of whether this portfolio can sustain double-digit growth and fully offset the multi-billion dollar hole left by Stelara's patent expiry.
